Journal of Research in Pharmaceutical Economics最新文献

The Evolution of Comorbidity Research:: Evaluation of Concurrent Chronic Conditions 共病研究的演变:并发慢性疾病的评估

Journal of Research in Pharmaceutical Economics Pub Date : 2001-06-01 DOI: 10.1300/J063V11N03_02

R. Garis

引用次数: 0

Modeling a Switch of Loratadine from Prescription to Over-the-Counter Status 氯雷他定从处方到非处方状态转换的建模

Journal of Research in Pharmaceutical Economics Pub Date : 2001-06-01 DOI: 10.1300/J063V11N03_04

Joshua Cohen

引用次数: 7

National Health Ensurance:: The Foundation for Building Optimal Health Policy 国家卫生保障::建立最佳卫生政策的基础

Journal of Research in Pharmaceutical Economics Pub Date : 2001-06-01 DOI: 10.1300/J063V11N03_11

T. Rucker

引用次数: 0

Pharmacogenetics and the role of the pharmacist 药物遗传学和药剂师的作用

Journal of Research in Pharmaceutical Economics Pub Date : 2001-06-01 DOI: 10.1300/J063V11N03_10

A. M. Zee, A. Boer, H. Leufkens

引用次数: 3

Proxy Reports in Pharmacoeconomic Studies:: Applications and Accuracy for Resource Utilization Estimates 药物经济学研究中的代理报告:资源利用估算的应用和准确性

Journal of Research in Pharmaceutical Economics Pub Date : 2001-06-01 DOI: 10.1300/J063V11N02_02

C. Evans

引用次数: 1

The Incremental Cost of Chronic Illnesses:: A Medicaid Database Analysis 慢性疾病的增量成本:医疗补助数据库分析

Journal of Research in Pharmaceutical Economics Pub Date : 2001-06-01 DOI: 10.1300/J063V11N03_03

R. Garis

引用次数: 2

The Financial Impact of Over-the-Counter Availability of Oral Contraceptive Pills 非处方口服避孕药的经济影响

Journal of Research in Pharmaceutical Economics Pub Date : 2001-06-01 DOI: 10.1300/J063V11N03_09

Mingfang Zhu, A. Wertheimer, R. Field

{"title":"The Financial Impact of Over-the-Counter Availability of Oral Contraceptive Pills","authors":"Mingfang Zhu, A. Wertheimer, R. Field","doi":"10.1300/J063V11N03_09","DOIUrl":"https://doi.org/10.1300/J063V11N03_09","url":null,"abstract":"In the United States today $40.7 billion is spent annually on nonsurgical contraception as well as the costs due to method failures. There are 60 million women of childbearing age (15-44 years) in the U.S.; of those an estimated 39 million use some form of contraception. Almost half of the 6 million pregnancies per year in the U.S. are unintended costing $22.5 billion annually. This is a huge market and many health care administrators look at it with the intention of locating savings. One possible avenue is moving oral contraceptives (OC) to over-the-counter (OTC) status. This would negate the need for many physician visits and consumers could purchase extremely effective contraceptive means without having to visit a medical doctor. Many women do not have access to physicians and due to financial constraints cannot afford to visit a physician. Some teenagers do not want their parents to know they are sexually active. The decline in the teenage pregnancy rate from 1991 to 1996 Was largely related to condom use and adoption of injectable and implant contraception. However the need for a physicians prescription is a potential access barrier to OCs for many young women age 25 and younger. The pregnancy rate remains highest for women in their early twenties. The overall unintended pregnancy rate still remains unacceptably high. There are three major criteria provided by law for a drug to be moved from prescription to OTC status: safety efficacy and proper labeling. Within the scope of these criteria the drug should be nonaddictive; it should be for a self-diagnosable condition; it should have low potential ham in case of incorrect use; it should have mild side effects that can be largely self-diagnosable; and the labeling should be written in a comprehensive way to enable unsupervised use. (excerpt)","PeriodicalId":269103,"journal":{"name":"Journal of Research in Pharmaceutical Economics","volume":"97 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2001-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133909917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Pharmaceutical Market Impact of the Early 1990's Health Care Debate 20世纪90年代早期医疗保健辩论对医药市场的影响

Journal of Research in Pharmaceutical Economics Pub Date : 2001-06-01 DOI: 10.1300/J063V11N02_01

C. Mullins

引用次数: 2

Alternative Reimbursement Systems in Community Pharmacy:: Structure, Perceptions, and Performance 社区药房的替代报销制度:结构、观念和绩效

Journal of Research in Pharmaceutical Economics Pub Date : 2001-06-01 DOI: 10.1300/J063V11N02_04

L. Mackeigan

引用次数: 3

R&D Leverage- A Measure to Evaluate the Impact of R&D on Earnings of Pharmaceutical Companies 研发杠杆——一种评估制药公司研发对收益影响的方法

Journal of Research in Pharmaceutical Economics Pub Date : 2001-06-01 DOI: 10.1300/J063V11N03_05

Y. Bhagwat

引用次数: 14